Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. 2007

A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
Clinic for Pediatric-Oncology, -Hematology and Clinical Immunology, Heinrich Heine University Duesseldorf, Moorenstrasse 5, 40225 Düsseldorf. troeger@med.uni-duesseldorf.de

BACKGROUND Survivin, a member of the inhibitor of apoptosis protein (IAP) family is transiently expressed at low levels during normal hematopoesis but profoundly overexpressed in adult leukemia potentially contributing to leukemogenesis due to deregulated apoptosis and defective cell cycle control. Alternative splicing results in four different mRNA variants survivin, survivin2B, survivin-DeltaExon3 and survivin-3B, with distinct cellular localization patterns and anti-apoptotic potential. Due to co-localization of survivin and survivin-2B in the cytoplasm survivin-2B may permit interactive fine-tuning of survivin actions and moreover play an attenuating role in its anti-apoptotic function. Lack of survivin-2B is associated with disease progression of malignomas suggesting a differential role of these isoforms in tumorigenesis. METHODS We therefore determined the expression of the functional survivin splice variants performing RT- and real-time PCR in a purely pediatric cohort of 20 patients suffering from precursor B-ALL (BCP-ALL). RESULTS Here, we demonstrate for the first time in pediatric patients with precursor B-ALL an association between lower survivin-2B expression and affiliation to the high risk group. CONCLUSIONS The idea that survivin-2B may act as natural antagonist of survivin could potentially be used in novel approaches of anti-cancer treatment by influencing the proportional expression of the different splice variants.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008869 Microtubule-Associated Proteins High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules. Ensconsin,Epithelial MAP, 115 kDa,Epithelial Microtubule-Associate Protein, 115 kDa,MAP4,Microtubule Associated Protein,Microtubule Associated Protein 4,Microtubule Associated Protein 7,Microtubule-Associated Protein,Microtubule-Associated Protein 7,E-MAP-115,MAP1 Microtubule-Associated Protein,MAP2 Microtubule-Associated Protein,MAP3 Microtubule-Associated Protein,Microtubule Associated Proteins,Microtubule-Associated Protein 1,Microtubule-Associated Protein 2,Microtubule-Associated Protein 3,7, Microtubule-Associated Protein,Associated Protein, Microtubule,E MAP 115,Epithelial Microtubule Associate Protein, 115 kDa,MAP1 Microtubule Associated Protein,MAP2 Microtubule Associated Protein,MAP3 Microtubule Associated Protein,Microtubule Associated Protein 1,Microtubule Associated Protein 2,Microtubule Associated Protein 3,Microtubule-Associated Protein, MAP1,Microtubule-Associated Protein, MAP2,Microtubule-Associated Protein, MAP3,Protein 7, Microtubule-Associated,Protein, Microtubule Associated,Protein, Microtubule-Associated
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003374 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. 1,2-Benzopyrone Derivatives,1,2-Benzopyrones,Coumarin Derivative,Coumarine,1,2-Benzo-Pyrones,Benzopyran-2-ones,Coumarin Derivatives,Coumarines,1,2 Benzo Pyrones,1,2 Benzopyrone Derivatives,1,2 Benzopyrones,Benzopyran 2 ones,Derivative, Coumarin,Derivatives, 1,2-Benzopyrone,Derivatives, Coumarin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077022 Survivin An apoptosis inhibitory protein that contains a single baculoviral IAP repeat (BIR) domain. It associates with MICROTUBULES and functions to regulate cell proliferation as a component of the chromosome passage protein complex (CPC), performing essential roles for localization of the complex, chromosome alignment, segregation during MITOSIS and CYTOKINESIS, and assembly of the MITOTIC SPINDLE. It is expressed by fetal kidney and liver cells and highly expressed in ADENOCARCINOMA and high-grade LYMPHOMA. BIRC5 Protein,Baculoviral IAP Repeat-containing Protein 5,Baculoviral IAP Repeat containing Protein 5
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
December 2018, Genetic testing and molecular biomarkers,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
August 2007, Haematologica,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
May 2024, Genes, chromosomes & cancer,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
December 2016, Indian pediatrics,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
September 2017, Blood,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
June 2023, Lymphatics,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
March 2011, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
April 2012, Leukemia,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
January 2021, Clinical laboratory,
A Tröger, and M Siepermann, and C Mahotka, and N Wethkamp, and H Bülle, and H-J Laws, and G Escherich, and G Janka-Schaub, and U Göbel, and D Dilloo
September 2017, Expert review of hematology,
Copied contents to your clipboard!